Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Clin Med ; 13(4)2024 Feb 18.
Artículo en Inglés | MEDLINE | ID: mdl-38398457

RESUMEN

BACKGROUND: We conducted a retrospective epidemiological study about the prevalence of stage 5 chronic kidney disease (CKD) in a high-income district, comparing some demographic characteristics and outcomes of those patients who had nephrological consultations and those who had not. RESULTS: In a district of 400,000 adult subjects in 2020, 925 patients had an estimated glomerular filtration rate (eGFR) under 15 mL/min and CKD. In the same period, 747 (80.4%) patients were assessed by nephrologists, while 178 (19.6%) were not. Age (88 vs. 75, p < 0.0001), female gender (66.3% vs. 47%, p < 0.001), and eGFR (12 vs. 9 mL/min, p < 0.001) were significantly different in the patients assessed by a nephrologist as compared those who did not have nephrological care. Furthermore, unfollowed CKD patients had a significantly higher death rate, 83.1% versus 14.3% (p < 0.0001). CONCLUSIONS: About 20% of ESKD patients did not receive a nephrologist consultation. Older people and women were more likely not to be referred to nephrology clinics. Unfollowed patients with stage 5 CKD had a significantly higher death rate.

2.
Int J Artif Organs ; 46(6): 344-350, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37066442

RESUMEN

Sepsis is one of the major causes of death worldwide. In its physiopathological process, a broad spectrum of pro and antiinflammatory mediators plays a strategic role, leading to a sepsis induced state of immunoparalysis. The rationale behind the employment of extracorporeal purification techniques as a complement to therapy for sepsis is based on their ability to remove the mediators involved. Until now, attention was focused on the immunomodulation allowed by purification therapies. However, the focus of studies on the application possibilities that these techniques offer as a supplement to antimicrobial therapy and resuscitation of critically ill patients must be extended. In this study, the possible removal by adsorption that the Jafron® HA330 cartridge operates against bacteria (S. aureus) was evaluated in vitro. Subsequently, it was evaluated whether the adsorptive capabilities toward bacteria were maintained by using a cartridge functionalized with Vancomycin and whether the latter maintains its bactericidal activity. This study showed that HA330 reduces the circulating bacterial load, even in the presence of pre-adsorbed Vancomycin. Vancomycin, once adsorbed by the cartridge, does not guarantee its bactericidal activity during the 2-h of hemoperfusion treatment.


Asunto(s)
Hemoperfusión , Sepsis , Humanos , Vancomicina , Staphylococcus aureus , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Sepsis/tratamiento farmacológico , Sepsis/microbiología , Hemoperfusión/métodos , Bacterias
4.
J Pharmacol Exp Ther ; 321(3): 961-7, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17329552

RESUMEN

The compound SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol] was recently identified as a selective antagonist for the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP). In the present study, the in vitro pharmacological profile of SB-612111 at human recombinant NOP receptors expressed in Chinese hamster ovary (CHO) cells [receptor binding, guanosine 5'-O-(3-[(35)S]thio)triphosphate (GTPgamma[(35)S]) binding, and cAMP level experiments] as well as at native NOP receptors expressed in peripheral (mouse and rat vas deferens, guinea pig ileum) and central (mouse cerebral cortex synaptosomes releasing [(3)H]5-HT) preparations was evaluated and compared with that of the standard nonpeptide antagonist (+/-)J-113397 [(+/-)-trans-1-[1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one]. SB-612111 produced a concentration-dependent displacement of [(3)H]N/OFQ binding to CHO(hNOP) cell membranes, showing higher affinity and NOP selectivity over classical opioid receptors than (+/-)J-113397. SB-612111 and (+/-)J-113397 competitively antagonized the effects of N/OFQ on GTPgamma[(35)S] binding in CHO(hNOP) cell membranes (pK(B), 9.70 and 8.71, respectively) and on cAMP accumulation in CHO(hNOP) cells (pK(B), 8.63 and 7.95, respectively), being per se inactive. In isolated peripheral tissues of mice, rats, and guinea pigs and in mouse cerebral cortex synaptosomes preloaded with [(3)H]5-HT, SB-612111 competitively antagonized the inhibitory effects of N/OFQ, with pA(2) values in the range of 8.20 to 8.50. In parallel experiments, (+/-)J-113397 was found to be 2- to 9-fold less potent than SB-612111. In the electrically stimulated tissues, 1 microM SB-612111 did not modify the effects of classical opioid receptor agonists. In conclusion, the results of the present study demonstrated that SB-612111 is among the most potent and NOP-selective nonpeptide antagonists identified to date.


Asunto(s)
Cicloheptanos/farmacología , Antagonistas de Narcóticos , Péptidos Opioides/antagonistas & inhibidores , Fragmentos de Péptidos/antagonistas & inhibidores , Piperidinas/farmacología , Animales , Bencimidazoles/metabolismo , Bencimidazoles/farmacología , Unión Competitiva/efectos de los fármacos , Células CHO , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Colforsina/farmacología , Cricetinae , Cricetulus , AMP Cíclico/metabolismo , Cicloheptanos/metabolismo , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Cobayas , Humanos , Íleon/efectos de los fármacos , Íleon/metabolismo , Técnicas In Vitro , Masculino , Ratones , Antagonistas de Narcóticos/metabolismo , Antagonistas de Narcóticos/farmacología , Péptidos Opioides/metabolismo , Fragmentos de Péptidos/metabolismo , Piperidinas/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores Opioides/genética , Receptores Opioides/metabolismo , Sinaptosomas/efectos de los fármacos , Sinaptosomas/metabolismo , Transfección , Conducto Deferente/efectos de los fármacos , Conducto Deferente/metabolismo , Receptor de Nociceptina
5.
Bioorg Med Chem ; 14(3): 692-704, 2006 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-16202610

RESUMEN

To date, J-113397 represents the most potent and selective non peptide NOP receptor antagonist widely used in pharmacological studies. However, the synthesis, purification, and enantiomer separation of this molecule, which contains two chiral centers, is rather difficult and low-yielding. Here, we synthesized and tested a series of simplified J-113397 analogues to investigate the importance of the stereochemistry and the influence of the substituents at position 3 of the piperidine nucleus and on the nitrogen atom of the benzimidazolidinone nucleus. The compound coded as Trap-101, an achiral analogue of J-113397, combines a pharmacological profile similar to that of the parent compound with a practical, high-yielding preparation.


Asunto(s)
Bencimidazoles/química , Bencimidazoles/farmacología , Antagonistas de Narcóticos , Piperidinas/química , Piperidinas/farmacología , Animales , Bencimidazoles/síntesis química , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Cobayas , Humanos , Técnicas In Vitro , Masculino , Ratones , Modelos Moleculares , Piperidinas/síntesis química , Receptores Opioides/genética , Receptores Opioides/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Estereoisomerismo , Conducto Deferente/efectos de los fármacos , Conducto Deferente/fisiología , Receptor de Nociceptina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA